Realistic best case scenario - around $10 in my opinion. That tirasemtiv drug is very interesting to me. The question is whether or not improving muscle endurance actually improves QoL for ALS patients. If it does, you're looking at a 100k-200k drug for a patient pop of about 30k. So 2B in income for a stock that trades near cash. I think its worth it.